Treating cancer with selective CDK4/6 inhibitors

@article{OLeary2016TreatingCW,
  title={Treating cancer with selective CDK4/6 inhibitors},
  author={Ben O'Leary and Richard S. Finn and Nicholas C. Turner},
  journal={Nature Reviews Clinical Oncology},
  year={2016},
  volume={13},
  pages={417-430}
}
Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological process. Clinical implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents. The emergence of a new generation of selective CDK4/6… Expand
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
TLDR
Several cancer-relevant signaling pathways, such as the MAPK and PI3K pathways, drive cell cycle progression and contribute to CDK activity, suggesting that concomitant inhibition of these pathways may delay the outgrowth of CDKi-resistant cells. Expand
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
TLDR
Current knowledge about the mechanisms and efficacy of CDK4/6 inhibitors are reviewed, and data on resistance mechanisms are summarized to make future combination therapies more accurate and reasonable. Expand
CDK4/6 blockade in breast cancer: current experience and future perspectives
TLDR
Future clinical development of CDK4/6 inhibitors in breast cancer will focus on the following aspects: optimization of treatment sequencing for patients with advanced disease, early-stage disease, other subtypes of breast cancer in rationally chosen therapeutic combinations and the identification of predictive biomarkers. Expand
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
TLDR
The data from clinical trials of CDK inhibitors in solid tumors, either as a monotherapy or in combination with other agents, are reviewed, with an emphasis on novel agents and potential new indications for this drug class. Expand
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
TLDR
This review summarizes the available knowledge regarding CDK4/6 inhibitor, the discovery of new biomarkers of response, and the biological rationale for new combination strategies of treatment. Expand
Targeting CDK9 for Anti-Cancer Therapeutics
TLDR
Significantly enhanced activity of CDK9 is observed in multiple cancer types, which is universally associated with significantly shortened Overall Survival of the patients, offering the rationale to target it using small-molecule inhibitors. Expand
How selective are clinical CDK4/6 inhibitors?
TLDR
It is emphasized the importance of comprehensively characterizing drugs' selectivity profiles to maximize their clinical efficacy and safety and to facilitate their repurposing to treat additional diseases based on their target spectrum. Expand
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
TLDR
It is shown that treatment with CDK4/6 inhibitors in both ER+ breast cancer and KRAS-mutant NSCLC cells induces feedback upregulation of cyclin D1,CDK4, and cyclin E1, mediating drug resistance, and rocaglates, which preferentially target translation of key cell-cycle regulators, effectively suppress this feedback up regulation induced by CDK 4/6 inhibition. Expand
An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
TLDR
The role of CDKs in cell-cycle regulation and tumorigenesis and recent advances in the development ofCDKs inhibitors as a promising therapy for the treatment of advanced cancer are summarized. Expand
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
TLDR
Ongoing research is evaluating CDK4/6i for additional breast cancer subtypes and non-breast malignancies with promising early phase clinical trial results and exploring potential resistance mechanisms to this treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 233 REFERENCES
Targeting cell cycle and hormone receptor pathways in cancer
TLDR
It is shown that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Expand
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
TLDR
CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt 3 wt AML, and acquired resistance to CDK 4/6 inhibition can arise through activation CDK2. Expand
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
TLDR
The data show that LEE011 is active in a large subset of neuroblastoma cell line and xenograft models, and supports the clinical development of this CDK4/6 inhibitor as a therapy for patients with this disease. Expand
The history and future of targeting cyclin-dependent kinases in cancer therapy
TLDR
How CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity is discussed. Expand
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
TLDR
The results support clinical trial evaluation of PD-0332991 against newly diagnosed as well as recurrent GBM, and indicate that Rb status is the primary determinant of potential benefit from this therapy. Expand
Pharmacologic inhibition of CDK 4 / 6 : mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation. We found that pharmacologic inhibition of the Flt3 internal tandem duplicationExpand
CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
TLDR
Replacing the IGF1R/IR inhibitor with the rapalog inhibitor temsirolimus broadened the sensitivity of PDAC cells to CDK4/6 inhibition and established targeted therapy combinations with robust cytostatic activity in p16(INK4A)-deficientPDAC cells. Expand
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
TLDR
A potent, orally active small-molecule inhibitor of CDK4/6 that is active in xenograft tumors and may be used alone or in combination with standard-of-care cytotoxic therapy is identified. Expand
A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.
TLDR
A phase 1 study to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LY2835219, a selective inhibitor of CDK4/6 that shows antitumors activity in preclinical models of human cancer and also distributes efficiently to the brain. Expand
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
TLDR
The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. Expand
...
1
2
3
4
5
...